Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

2(25%)

Results Posted

0%(0 trials)

Terminated

1(13%)

Phase Distribution

Ph early_phase_1

13%

Ph phase_2

63%

Ph not_applicable

13%

Ph phase_3

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Early Phase 1First-in-human

1(12.5%)

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

1(12.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Terminated1

Recruiting1

unknown1

Active, not recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (12.5%)

Phase 25 (62.5%)

Phase 31 (12.5%)

N/A1 (12.5%)

Trials by Status

completed338%

terminated113%

recruiting113%

unknown113%

active_not_recruiting113%

not_yet_recruiting113%

Recent Activity

2 active trials

Showing 5 of 8

recruitingphase_2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535

completednot_applicable

COL Immunotherapy Before Radiochimio + Ipilimumab

NCT04256213

active_not_recruitingphase_2

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

NCT03443856

unknownphase_3

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

NCT04741438

completedphase_2

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

NCT03620123

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02693535Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting

NCT04256213Not Applicable

COL Immunotherapy Before Radiochimio + Ipilimumab

Completed

NCT03443856Phase 2

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

Active Not Recruiting

NCT04741438Phase 3

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Unknown

NCT03620123Phase 2

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

Completed

NCT05597800Phase 2

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

Not Yet Recruiting

NCT03526185Early Phase 1

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Terminated

NCT03048474Phase 2

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8